COMPOSITION OF A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR

The invention encompasses a composition comprising the reverse transcriptase ("RT") inhibitor 3-chloro-5-({1-[(4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl}oxy)benzonitrile sufficiently mixed in a concentration enhancing polymer...

Full description

Saved in:
Bibliographic Details
Main Authors PLOEGER, KRISTIN J. M, TATAVARTI, ADITYA S, LOWINGER, MICHAEL, BAUMANN, JOHN M, BLOOM, COREY J, BROOKHART, KATHERINE ANNE, MARSAC, PATRICK JULES
Format Patent
LanguageEnglish
French
Published 08.01.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The invention encompasses a composition comprising the reverse transcriptase ("RT") inhibitor 3-chloro-5-({1-[(4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl}oxy)benzonitrile sufficiently mixed in a concentration enhancing polymer, and processes for making the same. The composition and processes of the present invention significantly improve the bioavailability of the aforementioned RT inhibitor, while maintaining physical stability. L'invention concerne une composition comprenant l'inhibiteur de transcriptase inverse (TI) 3-chloro-5-({1-[(4-méthyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)méthyl]-2-oxo-4-(trifluorométhyl)-1,2-dihydropyridin-3-yl}oxy)benzonitrile suffisamment mélangé à un polymère améliorant la concentration, et des procédés pour la préparer. La composition et les procédés selon la présente invention améliorent significativement la biodisponibilité de l'inhibiteur de TI susmentionné, tout en maintenant la stabilité physique.
Bibliography:Application Number: CA20142929499